Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: The prospective observational scoop trial results

Anti-Cancer Drugs

Volumn 28, Issue 1, 2017, Pages 104-109

  Pepa, Chiara Della ^a   Cavaliere, Carla ^c   Rossetti, Sabrina ^a   Di Napoli, Marilena ^a   Cecere, Sabrina C ^a   Crispo, Anna ^a   De Sangro, Carlo ^b   Rossi, Emanuela ^c   Turitto, Dino ^d   Germano, Domenico ^d   Iovane, Gelsomina ^a   Berretta, Massimiliano ^e   D'Aniello, Carmine ^a   Pisconti, Salvatore ^c   Maiorino, Luigi ^b   Daniele, Bruno ^d   Gridelli, Cesare ^c   Pignata, Sandro ^a   Facchini, Gaetano ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Cardiac Rehabilitation Unit of San Gennaro dei Poveri Hospital   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

^d G RUMMO HOSPITAL   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Comprehensive Geriatric Assessment; Docetaxel; Elderly; Prostate cancer

Indexed keywords

ABIRATERONE; CABAZITAXEL; CYCLOPHOSPHAMIDE; DOCETAXEL; ENZALUTAMIDE; IPILIMUMAB; NAVELBINE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; CUMULATIVE ILLNESS RATING SCALE FOR GERIATRICS; GERIATRIC ASSESSMENT; GERIATRIC DEPRESSION SCALE; HUMAN; LAWTON INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; LUBBEN SCALE; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; WEAKNESS; AGE; CLINICAL TRIAL; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; GERIATRIC ASSESSMENT; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 84984693670     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000428     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Morgia G, Russo GI, Berretta M, Privitera S, Kirkali Z. Genito-urological cancers in elderly patients. Anticancer Agents Med Chem 2013; 13:1391-1405.
3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-592.
4. De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P, et al. Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncol 2015; 11:3091-3098.
5. D'Aniello C, Cavaliere C, Cecere SC. GNRH analogues and its role in CRPC. WCRJ 2014; 1:e358.
6. Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, et al. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. Future Oncol 2015; 11:965-973.
7. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, et al. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of Docetaxel and other second-line treatment: results of an Italian Multicentre Study. Eur Urol 2015; 68:147-153.
8. Caffo O, Gernone A, Ortega C, Sava T, Cartenì G, Facchini G, et al. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol 2012; 107:191-196.
9. Berretta M, Tirelli U. Elderly cancer patients in the 3rd millenium: between hope and reality. Introduction. Anticancer Agents Med Chem 2013; 13:1299.
10. Caraglia M, Giuberti G, Marra M, Di Gennaro E, Facchini G, Caponigro F, et al. Docetaxel induces P53-dependent apoptosis and synergizes with farnesyltransferase inhibitor R115777 in human epithelialc ancer cells. Front Biosci 2005; 10:2566-2575.
11. Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients. Phase I ZANTE Trial. Cancer Biol Ther 2010; 10:543-548.
12. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242-245.
13. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
14. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
15. Malaguarnera M, Frazzetto PM, Erdogan O, Cappellani A, Cataudella E, Berretta M. Geriatric evaluation of oncological elderly patients. Anticancer Agents Med Chem., 2013; 13:1300-1309.
16. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55:241-252.
17. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993; 342:1032-1036.
18. Stuck AE, Egger M, Hammer A, Minder CE, Beck JC. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. JAMA 2002; 287:1022-1028.
19. Extermann M, Meyer J, McGinnis M, Crocker TT, Corcoran MB, Yoder J, et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 2004; 49:69-75.
20. Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, et al. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc 2006; 54:1119-1124.
21. Girre V, Falcou MC, Gisselbrecht M, Gridel G, Mosseri V, Bouleuc C, et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? J Gerontol A Biol Sci Med Sci 2008; 63:724-730.
22. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179-186.
23. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16:622-626.
24. Lyness JM, Noel TK, Cox C, King DA, Conwell Y, Caine ED. Screening for depression in elderly primary care patients. A comparison of the Center for Epidemiologic Studies-Depression Scale and the Geriatric Depression Scale. Arch Intern Med 1997; 157:449-454.
25. Lubben JE. Assessing social networks among elderly populations. Fam Community Health 1988; 3:42-52.
26. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
27. Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol., 2014; 5:119-126.
28. Takaha N, Okihara K, Kamoi K, Hongo F, Iwata T, Yano K, et al. Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer. Urol Int 2011; 87:263-269.
29. Miyake H, Sakai I, Harada K, Muramaki M, Fujisawa M. Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol., 2012; 44:1697-1703.
30. Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55:1368-1376.
31. Giacalone A, Quitadamo D, Zanet E, Berretta M, Spina M, Tirelli U. Cancer-related fatigue in the elderly. Support Care Cancer 2013; 21:2899-2911.
32. Giacalone A, Spina M, Berretta M, Tirelli U. Two types of fatigue in cancer patients. Br J Cancer 2012; 106:424.
33. Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. PROSTY study group. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14:117-124.
34. Wong HL, Lok SW, Wong S, Parente P, Rosenthal M. Docetaxel in very elderly men with metastatic castration-resistant prostate cancer. Prostate Int 2015; 3:42-46.
35. Della Pepa C, D'Aniello C, Rossetti S, Iovane G, Pisconti S, Fisichella R, et al. 'Real-life' effectiveness studies in mCRPC patients: systematic review. WCRJ 2015; 2:e617.
36. Terret C, Albrand G, Droz JP. Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer 2004; 2:236-240.
37. Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005; 16:1795-1800.
38. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc 2011; 59:1837-1846.
39. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Background for the establishment of SIOG Guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010; 73:68-91.
40. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15:404-414.
41. Mourey L, Gravis G, Sevin E. Feasibility of docetaxel-prednisone (DP) in frail elderly (age 75 or older) patients with castration-resistant metastatic prostate cancer (CRMPC): GERICO10-GETUG P03 trial led by Unicancer. J Clin Oncol Meet Abstr 2014; 32:152.
42. Berretta M, Di Francia R, Tirelli U. The new oncologic challenges in the 3RD millennium. WCRJ 2014; 1:e133.
43. Marra M, Santini D, Tonini G, Meo G, Zappavigna S, Facchini G, et al. Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. Eur J Cancer 2008; 6:79-85.
44. Franco R, Caraglia M, Facchini G, Abbruzzese A, Botti G. The role of tissue microarray in the era of target-based agents. Expert Rev Anticancer Ther 2011; 11:859-869.
45. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
46. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
47. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-148.
48. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197.
49. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371:424-433.